Pamapimod

Pamapimod is an investigational drug which is being evaluated for the treatment of autoimmune diseases. It is a p38 mitogen-activated protein kinase inhibitor. It has been evaluated in a phase 2 clinical trial for the treatment of rheumatoid arthritis, but was found not to be effective. It has subsequently been investigated as a possible treatment for osteoarthritis.